Safety and Efficacy Trial of Mass Drug Administration With Moxidectin Versus Ivermectin in Combination With Diethylcarbamazine and Albendazole for Lymphatic Filariasis, Scabies, and Strongyloidiasis in Fiji

The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases are common. The main questions it aims to answer are:
1. Does MoxDA clear infection in people with lymphatic filariasis ?
2. Does MoxDA cause any medical problems in infected and uninfected people?
Researchers will compare MoxDA with ivermectin given together with diethylcarbamazine and albendazole (IDA) to see if it works better to clear infection and does not cause any more medical problems.
Participants will:
1. Be tested to see if they are infected with the parasites that cause lymphatic filariasis, scabies and strongyloidiasis
2. Take 3 single doses of MoxDA or IDA, 12 months apart
3. Visit their village centre once or twice in the 1 week after each treatment for safety checkups

Start Date01 Mar 2026

Sponsor / Collaborator

Medicines Development for Global Health Ltd

[+2]

NCT07145736

/ RecruitingPhase 4

Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases: A Cluster-randomised Trial

This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Both drugs are approved by the United States Food and Drug Administration (FDA) to treat this disease. The study also explores how these treatments affect other infections common in the region, including intestinal worms (soil-transmitted helminths) and scabies.
The trial aims to answer the following key questions:
* How do moxidectin and ivermectin compare in reducing the prevalence (how common the disease is) and intensity (amount of parasites per person) of onchocerciasis in the community?
* Do the treatments differ in their effect on the prevalence and intensity of soil-transmitted helminths and the prevalence of scabies?
* Does moxidectin reduce transmission of onchocerciasis more effectively than ivermectin, based on genetic testing of parasites in people and lab testing of the blackflies that carry the infection?
* How many more years of treatment would be needed to reach elimination with each drug, based on mathematical disease modelling?
* How do communities feel about receiving moxidectin versus ivermectin, and what factors help or make it harder to carry out MDA programs with moxidectin versus ivermectin?
The study takes place in Bié Province, Angola, and involves 20 groups of villages randomly assigned to receive either moxidectin or ivermectin once a year for four years. Prior to every round of MDA, researchers will collect skin, stool and blood samples from a sample of the people living in the study area. We believe the results will help guide global policy on the use of moxidectin in efforts to eliminate onchocerciasis and control related diseases.

Start Date04 Aug 2025

Sponsor / Collaborator

Kirby Institute

[+9]

100 Clinical Results associated with Moxidectin

100 Translational Medicine associated with Moxidectin

100 Patents (Medical) associated with Moxidectin

1,047

Literatures (Medical) associated with Moxidectin

01 Mar 2026·ENVIRONMENTAL RESEARCH

Independent impacts of co-formulants contained in anthelmintic formulations on seed germination of grassland species

Article

Author: García, Andrés ; Jaß, Scarlett ; Eichberg, Carsten ; Donath, Tobias W ; Laber, Lars

Agrochemicals have been shown to affect non-target organisms and are often applied as mixtures of active ingredient and co-formulants. Although there is evidence that co-formulants play a role in these effects, their contribution has hardly been studied. Therefore, we studied effects of co-formulants on seed germination (percentage, time, synchrony) using a common anthelmintic formulation. The seeds of four species of temperate grasslands (Achillea ptarmica, Agrostis capillaris, Dianthus deltoides, Plantago lanceolata) were exposed to a commercial moxidectin formulation at a concentration of 10 mg l^-1 as well as three of its co-formulants: benzyl alcohol (BA), butylated hydroxytoluene (BHT) and disodium ethylenediamine tetraacetic acid (EDTA-Na₂). Results showed that the tested anthelmintic formulation as a whole and two of its co-formulants (BA, BHT) as individual substances significantly impacted germination behaviour of the test species. Formulation, BA and BHT significantly reduced germination percentage in all species compared to the control, with BA exerting the strongest effect (reduction up to 99 %). The same three treatments significantly increased mean germination time in all species by a factor of two to four. Germination synchrony showed a weaker response and was only affected in two species (A. capillaris, D. deltoides) and only by BHT (reduction of 49 % and 60 %, respectively). The strong effects of BA and BHT on seed germination suggest that their contribution to effects of anthelmintic formulations is at least partly due to an independent impact. Therefore, co-formulants should be given greater consideration both in the design of ecotoxicological experiments and in environmental risk assessments.

01 Feb 2026·VETERINARY PARASITOLOGY

Integrated pharmacokinetic–pharmacodynamic analysis of macrocyclic lactones in sheep infested with resistant Psoroptes ovis

Article

Author: Miró, Victoria ; Herrera, Rodolfo ; Lifschitz, Adrián ; Larroza, Marcela

The current study aimed to investigate the pharmacokinetic/pharmacodynamic (PK/PD) relationship of five macrocyclic lactone (MLs) formulations, three 1 % formulations (ivermectin, doramectin and moxidectin) and two long-acting 3.15 % products (ivermectin and doramectin), against sheep experimentally infested with resistant Psoroptes ovis under standardized doses. Thirty naïve Merino sheep were experimentally infested and randomly assigned to five treatment groups (n = 6). Baseline mite counts were not used to block animals during group allocation. The three 1 % formulations of ivermectin (IVM), doramectin (DRM), and moxidectin (MXD), were administered off-label at a dose of 0.5-0.6 mg/kg on days 0 and 7, subcutaneously. The long-acting 3.15 % formulations were subcutaneously administered once at their approved doses of 1.05 mg/kg (IVM 3.15 %) and 1.26 mg/kg (DRM 3.15 %). Plasma drug concentrations and mite counts were assessed between 0 and 35 days post-treatment. Conventional 1 % formulations produced higher peak plasma concentrations than long-acting formulations, although the latter showed greater persistence, similar to that observed with repeated MXD 1 %. DRM 1 % showed greater systemic exposure compared to 3.15 % long acting formulations and IVM 1 %. Significant reductions in mite counts were observed by day 7 with DRM 1 %, and by day 14 with IVM 1 % and MXD 1 %. In contrast, long-acting formulations showed delayed responses, with significant reductions only by day 21. Only DRM 1 % and MXD 1 % achieved 100 % efficacy. PK/PD indices established for ML-resistant P. ovis were calculated as the ratio between peak plasma concentration (Cmax) and the minimal inhibitory concentration (MIC) values of 15 and 30 ng/mL (Cmax/MIC), as well as the ratios between the area under the concentration-time curve (AUC) and the same MIC values (AUC/MIC). The Cmax/MIC ratio observed for 1 % formulations were significantly higher compared to those obtained with the long-acting formulations at both MIC levels. For the AUC/MIC parameter, the 1 % formulations exhibited significantly higher values compared to the long-acting formulations for the MIC 30 ng/mL.These findings suggest that both the magnitude and duration of MLs in plasma are critical for efficacy against P. ovis.

09 Jan 2026·JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION

Topically administered macrocyclic lactone products, including eprinomectin, demonstrate comparable neurological safety in cats based on pharmacovigilance data

Article

Author: Frana, Timothy ; Novotny, Mark J. ; Geary, Timothy G. ; Silva, Marcelo

Abstract:

Objective:

The purpose of the study was to evaluate the proportional reporting of neurological adverse events (AEs) associated with feline topical parasiticide products containing macrocyclic lactones (MLs; including eprinomectin) and emodepside by use of postapproval pharmacovigilance data. The intent was to provide veterinarians prescribing these products for their feline patients with the overall comparative context of neurological AE reporting for these products, which have been characterized as substrates for P-glycoprotein transporters.

Methods:

The openFDA and EudraVigilance Veterinary Data Warehouse databases were queried for neurological AEs cumulatively reported through December 31, 2024, for marketed parasiticide products containing MLs (eprinomectin, selamectin, moxidectin) and emodepside for topical administration to cats. The frequencies of neurological AE reporting were compared between products with proportional report rates and disproportionality statistical measures.

Results:

The reporting frequencies of neurological AEs associated with these feline topical parasiticide products were similar. For all products, ataxia was the most frequently reported neurological AE, with proportional report rates ranging from 5.3% to 14.0%. Proportional report rates ranged from 1.7% to 10.7% for convulsion and muscle tremor.

Conclusions:

An evaluation of pharmacovigilance data from 2 different sources revealed no evidence of greater proportional reporting for neurological AEs specific to the use of eprinomectin-containing products in cats than for other MLs or emodepside.

Clinical Relevance:

These findings supported the conclusion that ML-containing products (including eprinomectin-containing products) and emodepside are comparable in the frequencies and types of neurological AEs associated with feline topical parasiticide products described as substrates for P-glycoprotein transporters.

News (Medical) associated with Moxidectin

27 Oct 2025

·www.prnewswire.com

Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species

FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-legged ticks (lxodes scapularis) and protection against the longhorned tick (Haemaphysalis longicornis), which is rapidly spreading, now reaching 22 states.i The Companion Animal and Parasite Council tracker shows more than 422,000 cases of Lyme disease in dogs so far this year,ii surpassing the total number of annual cases seen in all of 2019.iii Elanco continues to go beyond for veterinarians and pet owners, providing even more comprehensive protection against some of the most concerning ticks. INDIANAPOLIS, Ind., Oct. 27, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced label expansions for two of its leading canine prescription parasiticides, Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio (lotilaner), with both product labels updated to include: Prevention of Lyme disease as a direct result of killing black-legged ticks (lxodes scapularis) Treatment and control of longhorned tick (Haemaphysalis longicornis) infestations Given the rising threat of ticks and tick-borne disease, this expanded protection for dogs is timely. The Companion Animal and Parasite Council tracker shows more than 422,000 cases of Lyme disease in dogs so far this year,ii surpassing the total number of annual cases seen in all of 2019.iii On the human side, the CDC reported that this May had the highest level of tick bites seen in human emergency room visits since 2019.iv Pets and people can encounter ticks in common areas like the backyard or simply walking around the neighborhood, so it is important for dogs to be protected with a flea and tick treatment year-round. "This label expansion is a testament to Elanco's unwavering commitment to innovation and scientific excellence," said Dr. Ellen de Brabander, Executive Vice President, Innovation and Regulatory Affairs, at Elanco. "Our research and development teams are constantly working to anticipate and address emerging threats, ensuring and demonstrating that Credelio Quattro and Credelio continue to provide leading-edge protection for dogs against a complex and evolving parasitic landscape." Lotilaner vs. Lyme Disease The active ingredient lotilaner in both Credelio Quattro and Credelio has been found highly effective for killing the black-legged vector ticks (lxodes scapularis), which are the most common spreaders of Lyme disease.v Both labels in the U.S. now include a claim for prevention of Lyme disease in dogs as a direct result of killing black-legged ticks. With more than 422,000 cases of Lyme disease in dogs already recorded this year, northeast states including New York, Maine, New Hampshire, Vermont, Pennsylvania and Connecticut are a few of the states with the most positive cases.ii And it's not just cases of Lyme disease in dogs that are on the rise. A 2021 estimate suggests that each year, approximately 476,000 Americans are diagnosed and treated for Lyme disease.vi "With this label expansion, pet owners and veterinarians now have more options to protect dogs from Lyme disease," said Dr. Casey Locklear, veterinarian and parasiticide lead for Elanco Animal Health. "With higher positive cases of canine Lyme disease already confirmed this year by the CAPC,iv pet owners should ask their veterinarian for parasite protection that includes protection against Lyme disease, like Credelio Quattro or Credelio." Lotilaner vs. Longhorned Tick The longhorned tick is an invasive tick species that is rapidly spreading and is now in 22 states around the country,i posing a significant threat to animal and human health. The ticks' ability to transmit canine pathogens, like Ehrlichia and Babesia species also highlights its potential risk for dogs as the population continues to spread across the country.vii "The unique biology of the longhorned tick is what makes it a potential public health challenge," said Dr. Locklear. "They can establish populations of thousands from a single female because they have the ability to reproduce without mates." In a recent peer-reviewed and published study in Parasites and Vectors, both Credelio Quattro and Credelio demonstrated 100% efficacy against the longhorned tick at 48 hours after infestation and continuing throughout the month.viii Lotilaner vs. Lone Star Tick While both Credelio Quattro and Credelio were already approved to protect dogs from the lone star tick (Amblyomma americanum), the rise in tick infestations across the country reinforces the need for effective parasite control. This aggressive and expanding tick species is found across the country, is one of the hardest to kill, and is best known for its association with alpha-gal syndrome (red meat allergy) in humans. It can also transmit dangerous disease-causing pathogens to dogs.iv The active ingredient lotilaner in both Credelio Quattro and Credelio kills the lone star tick faster* than sarolaner in Simparica Trio® and afoxolaner in NexGard®, protecting dogs against this pathogen-carrying tick. "It is critical that veterinarians talk with pet owners about year-round parasite protection," said Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University. "The rapid and sustained speed of tick kill of Credelio Quattro and Credelio helps protect dogs against pathogen-carrying ticks which can result in dangerous diseases." "This expanded label for Credelio Quattro and Credelio is exciting for pet owners and veterinarians alike," said Bobby Modi, Executive Vice President, U.S. Pet Health and Digital Transformation at Elanco. "Our expanded label demonstrates even more comprehensive protection against some of the most concerning ticks, going beyond for both pet owners and veterinarians and helping dogs live healthier, happier, more active lives." To learn more about Credelio Quattro and Credelio and how they protect against emerging parasite threats, please visit QuattroDogVet.com and . ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at . CREDELIO INDICATIONS Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks. CREDELIO IMPORTANT SAFETY INFORMATION Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian. CREDELIO QUATTRO INDICATIONS Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks. CREDELIO QUATTRO IMPORTANT SAFETY INFORMATION Lotilaner, an ingredient in Credelio Quattro, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. For complete safety information, please see the Credelio Quattro product label or ask your veterinarian. NexGard is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. Simparica TRIO is a registered trademark of Zoetis Services LLC. Credelio, Credelio Quattro, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Other company and product names are trademarks of their respective owners. © 2025 Elanco or its affiliates i Triltsch, O. (2025, August 28). Tiny invaders: The rise of the Asian longhorned tick. Michigan United Conservation Clubs: Join Us Today! ii Companion Animal Parasite Council. Parasite Prevalence Maps – Lyme Disease in Dogs, United States, 2025 (All Year). Accessed September 24, 2025. iii Companion Animal Parasite Council. Parasite Prevalence Maps – Lyme Disease in Dogs, United States, 2019 (All Year). Accessed September 24, 2025. iv Centers for Disease Control and Prevention. (n.d.). Where Ticks Live. Centers for Disease Control and Prevention. Retrieved August 8, 2024, from v Murphy M, Garcia R, Karadzovska D, Cavalleri D, Snyder D, Seewald W, Real T, Drake J, Wiseman S, Nanchen S. Laboratory evaluations of the immediate and sustained efficacy of lotilaner (Credelio™) against four common species of ticks affecting dogs in North America. Parasit Vectors. 2017 Nov 1;10(1):523. doi: 10.1186/s13071-017-2476-y. PMID: 29089057; PMCID: PMC5664823. vi Kugeler, K. J., Schwartz, A. M., Delorey, M. J., Mead, P. S., & Hinckley, A. F. (2021). Estimating the Frequency of Lyme Disease Diagnoses, United States, 2010–2018. Emerging Infectious Diseases, 27(2), 616-619. . vii Dye-Braumuller KC, Gual-Gonzalez L, Abiodun T, Rustin LP, Evans CL, Meyer MM, Zellars K, Neault MJ, Nolan MS. Invasive Haemaphysalis longicornis (Acari: Ixodidae) investigation in South Carolina: new records of establishment, pathogen prevalence, and blood meal analyses. J Med Entomol. 2023 Nov 14;60(6):1398-1405. doi: 10.1093/jme/tjad119. PMID: 37658780; PMCID: PMC10645392. viii Wiseman, S., Savadelis, M.D., Maree, R. et al. Efficacy of Credelio Quattro™ (lotilaner, moxidectin, pyrantel, praziquantel) and Credelio™ (lotilaner) against longhorned tick, Haemaphysalis longicornis,-induced infestations on dogs. Parasites Vectors 18, 344 (2025). * Based on time to statistical significance vs control in a head-to-head study. The study compared Credelio™ (lotilaner)—not Credelio Quattro™, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio™ (sarolaner, moxidectin, and pyrantel) and NexGard™ (afoxolaner) Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected] Media Contact: Season Solorio (765) 316-0233 [email protected] SOURCE Elanco Animal Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

21 May 2025

·www.einpresswire.com

Veterinary Dermatology Drugs Market to Reach $32.1 Billion by 2035, Rising from $17.6 Billion in 2024 at 8.8% CAGR

As pet insurance coverage increases and consumers demand higher standards of care, the veterinary dermatology drugs market is set to grow steadily. INDORE, INDIA, May 21, 2025 / EINPresswire.com / -- Veterinary dermatology drugs market was valued at $19.8 billion in 2024 and is anticipated to grow at a CAGR of 8.8% during the forecast period (2025-2035). Increasing pet ownership, a growing number of dermatology drugs clinical trials and approvals, an increasing rate of parasitic and other skin diseases in animals, and market players' investments are the primary drivers of the market growth. For instance, in September 2024, the FDA approved Zenrelia (ilunocitinib tablets), an oral immunosuppressant for the treatment of itching and atopic dermatitis in dogs aged one year and older. Zenrelia is accessible by prescription and has several tablet strengths. The emergence of new and targeted therapies, such as biologics and natural-based products, is further driving market growth. Veterinarians are now moving toward a more individualized treatment of skin conditions in animals, helping the trend toward more specialized and accurate treatment options. For instance, in August 2024, Boehringer Ingelheim India entered into a strategic distribution collaboration with Vvaan Lifesciences Pvt Ltd to strengthen its pet parasiticide portfolio and increase its foothold in the pet health space in India, worth approximately $124.51 million. With this partnership, the company focuses on enhancing quality pet healthcare in Tier 2 and smaller cities, utilizing the knowledge of Vvaan to offer better services in these areas as well as enhancing veterinary care levels throughout the country. Click To get a Sample PDF (Including Full TOC, Graphs & Charts, Table & Figures) @ https://www.omrglobal.com/request-sample/veterinary-dermatology-drugs-market Market Trends Rising Pet Acquisition and Spending on Pet Health to Propel Market Growth The surging trend towards the ownership of pets, especially among millennials and Gen Z, has been a dominant growth force within the market of veterinary dermatology drugs. Pets are considered family more and more, with all that follows their well-being that increases attention being devoted to skin, as part of overall pet wellness. That means more spending on veterinary health treatments, such as dermatological medications for problems of allergies, infection, and dermatitis. Pet owners are more conscious of the importance of curing skin disorders in pets, and this is increasing the demand for specific dermatology drugs. As there is an increasing growth in the pet care industry, both in developed and emerging economies, demand for safe, effective, and low-cost veterinary dermatology drugs is expected to rise, thereby driving market growth. For instance, in September 2024, Elanco launched Zenrelia (ilunocitinib tablets), an oral once-daily JAK inhibitor for the control of canine atopic and allergic dermatitis in dogs 12 months of age and older. Zenrelia offers excellent itch relief and value, making it a safer and more effective alternative to others. Advancements in Veterinary Dermatology Products to Fuel Market Growth Technological advancements and innovations in veterinary dermatology drugs are significant market drivers. Growing numbers of more specific and more efficient dermatology drugs for pets have improved the success rates for the treatment of numerous skin diseases, including atopic dermatitis, bacterial infestations, and parasitic infestations. All this has led to the use of new forms of drugs, biologics, and immunotherapy preparations that are more effective with fewer side effects compared to the traditional treatment. In addition, the increasing use of such drugs in animal clinics and better diagnostic equipment for dermatology conditions have contributed to improving their application. The progress of veterinary dermatology through innovative treatments, the demand for specialized drugs to treat complicated skin diseases in animals, will drive market growth. Order Your Report Now For A Swift Delivery: https://www.omrglobal.com/buy-now/veterinary-dermatology-drugs-market Regional Outlook North America Holds a Major Market Share North America holds a majority of market share, this is primarily due to the rising number of pets in developed nations such as the US and Canada and the accessibility of leading veterinary dermatology companies in the region. Increased pet healthcare spending, better-equipped veterinary infrastructure, and greater awareness regarding animal dermatological disorders are further contributing to increased demand for veterinary dermatology products in the region. The rising number of veterinary professionals in North America helps drive market growth. According to the Workforce Needs in Veterinary Medicine report prepared by the National Academy of Sciences states that the active veterinarians in the region were ~90,200 in 2012; this is expected to grow to 108,900 by 2030. The growth in veterinary clinics is projected to increase access to high-end diagnostic and therapeutic solutions, fueling the demand for veterinary dermatology products in North America. Additionally, developments in veterinary dermatological therapies, including monoclonal antibody therapies (such as Cytopoint) and new topical therapies, are driving the market. Asia-Pacific is the fastest-growing region of Veterinary Dermatology Drugs Asia-Pacific is anticipated to register the fastest CAGR during the forecast period. Due to rising growth in economies of the Asia-Pacific region, there is an apparent increase in the number of middle-class populations, increased disposable incomes, and growing urbanization. Market Players have started to grasp opportunities in such developing markets. China, specifically, enjoys high momentum on the back of advancements in veterinary drugs and government backing for pet care. For instance, in October 2024, China's Ministry of Agriculture and Rural Affairs approved FelicaMed Biotechnology's Lirucitinib, a Class I animal drug for the treatment of canine pruritus. Licensed to a Chinese subsidiary, Elanco, Lirucitinib is a JAK inhibitor that disrupts the itch-scratch-inflammation cycle, offering instant relief. This collaboration is a landmark in China's veterinary innovation and reaffirms FelicaMed's focus on improving pet health solutions. Moreover, partnerships among local firms and international leaders (such as FelicaMed and Elanco in China) are fueling the launch of innovative medicines tailored to regional market requirements. Market Segmentation and Growth Areas Companion Animal is expected to become the Largest Segment Growth in pet adoption has thus promoted a greater demand for quality pet products and services. This increase has been contributed to by improved knowledge of the pet requirements as a result of advances in veterinary medicine, along with information spreading on the subject. Owners are providing high preference for high-class pet foods, toys, and other health items for animals. Topical segment to occupy a Considerable Market Share Topical drugs have high specificity and may easily be applied directly at the site of disease without being injected into blood streams, hence reducing overall body reactions or changes from other drug components. Topical drugs are favored by veterinarians because they are easier to deliver than oral suspensions and tablets. They offer quicker relief when applied to the diseased spot and may be employed in the treatment of many skin ailments. While the need for quality therapy options by consumers continues to increase, the topical category is at the forefront in regards to animal health care solutions innovation targeted at efficacy, safety, and ease of use. Market Limitations and Challenges • Lack of Awareness among Pet Owners: Pet owners usually don't recognize dermatological signs or symptoms for veterinary intervention. Such ignorance can lead to undertreatment and underdiagnosis of animal skin disease. • Shortage of Dermatology-Veterinary Trained Specialists: There is a global shortage of veterinarians with dermatology training, contributing to inaccurate diagnosis and treatment. This leaves a gap in sophisticated dermatological treatment, particularly in rural and underprivileged communities. Market Players Outlook Some of the key players in the global veterinary dermatology drugs market are Bimeda, Inc., Ceva Sante Animale, Elanco, Merck & Co., Inc., and Zoetis Inc., among others. The players are emphasizing more business growth and product development by implementing strategies such as collaborations, mergers, and acquisitions to be competitive in the market. For instance, in November 2024, Bimeda, Inc. (Ireland) extended its anti-parasitic portfolio with the introduction of MoxiSolv Injection (moxidectin), the FDA-approved injectable, marketed in a non-shattering 500 mL plastic bottle. Request for Customization: https://www.omrglobal.com/report-customization/veterinary-dermatology-drugs-market Recent Developments • In November 2024, Merck & Co., Inc. (US) secured a European Commission grant for marketing authorization of BRAVECTO TriUNO, a new formulation of fluralaner in dogs for treating internal and external parasites, approved in Peru, Guatemala, Nicaragua, and Costa Rica. • In September 2024, Norbrook (Ireland) invested $1.5 million to formally launch the newly upgraded sterile injectable manufacturing site in Newry, Northern Ireland, to manufacture products that are vital in treating and preventing infection in livestock and pets. • In July 2024, Invetx (US) was acquired by Dechra Pharmaceuticals plc (UK) that is a company focusing on creating protein-based therapeutics for companion animals' chronic diseases using monoclonal antibodies (mAbs). Some of the Key Companies in the Veterinary Dermatology Drugs Market Include- • AB Science • Bayer AG • Bimeda Holdings Ltd. • Bioiberica S.A.U. • Boehringer Ingelheim International GmbH • Ceva Santé Animale • Elanco Animal Health Inc. • IDEXX Laboratories Inc. • Indian Immunologicals Ltd. • Leti Pharma, S.L.U. • Mars, Inc. • Merck & Co., Inc. • Novartis AG • SAVAVET • Toray Industries, Inc. • Vetoquinol Group • Virbac Corp. • Vivaldis Health & Foods Pvt. Ltd. • Zoetis Inc. Market Segmentation Analysis Global Veterinary Dermatology Drugs Market by Type • Antifungal Drugs • Antibacterial Drugs • Antiparasitic Drugs Global Veterinary Dermatology Drugs Market by Animal Type • Companion Animals • Livestock Animals Global Veterinary Dermatology Drugs Market by Route of Administration • Topical • Oral • Injectable Global Veterinary Dermatology Drugs Market by Distribution Channel • Hospital Pharmacies • Retail • E-commerce Global Veterinary Dermatology Drugs Market by Indication • Parasitic Infections • Allergic Infections • Others (Skin Cancer) Regional Analysis • North America o United States o Canada • Europe o UK o Germany o Italy o Spain o France o Rest of Europe • Asia-Pacific o China o India o Japan o South Korea o ASEAN Economies (Singapore, Thailand, Vietnam, Indonesia, and Other) o Australia and New Zealand o Rest of Asia-Pacific • Rest of the World o Latin America o Middle East and Africa Inquiry Before Buying: https://www.omrglobal.com/inquiry-before-buying/veterinary-dermatology-drugs-market Anurag Tiwari Orion Market Research Pvt Ltd + +91 91798 28694 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalAcquisition

15 Aug 2024

·www.prnewswire.com

Credelio® (lotilaner) Kills Ticks 2x as Fast as Simparica TRIO® (sarolaner, moxidectin and pyrantel) and NexGard® (afoxolaner)

Study finds that the aggressive lone star tick is no match for Credelio GREENFIELD, Ind., Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors, a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study demonstrating that Credelio, a prescription flea and tick protection product from Elanco Animal Health, has the fastest initial speed of tick kill in just 12 hours and sustains that advantage throughout the dosing interval.1,2,3 According to the Centers for Disease Control (CDC), during 2019 – 2022, state and local health departments reported more than 45,000 human cases of tickborne disease to CDC.4 The Companion Animal Parasite Council (CAPC) recommends using products on pets that kill and/or repel ticks before pathogens are transmitted.5 Continue Reading Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University, highlights the importance of the study findings. The 2023 head-to-head study compared three popular prescription flea and tick treatment products for dogs, Credelio (lotilaner), Simparica TRIO (sarolaner, moxidectin, pyrantel), and NexGard (afoxolaner), tracking the comparative data for the relative speeds of kill of Amblyomma americanum (lone star tick). The 2023 head-to-head study compared three popular prescription flea and tick treatment products for dogs, Credelio (lotilaner), Simparica TRIO (sarolaner, moxidectin, pyrantel), and NexGard (afoxolaner), tracking the comparative data for the relative speeds of kill of Amblyomma americanum (lone star tick) – an aggressive and expanding tick found in the United States that is one of the hardest to kill. Not only is this tick hard to kill, but it can also transmit dangerous disease-causing pathogens to pets and people. The CDC recently provided in-depth tick surveillance information regarding the aggressive nature of the lone star tick that can bite humans and transmit bacterial and viral pathogens, as well as cause alpha-gal syndrome (red meat allergy).6 "The results of this head-to-head study establishes Credelio as the front runner in speed of tick kill in prescription flea and tick treatment products for dogs.1 This is important because the longer a tick is attached, the greater the risk of pathogen transmission," said Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University. "These pathogens can cause serious diseases, such as Rocky Mountain Spotted Fever and ehrlichiosis, so it is critical that veterinarians talk with pet owners about year-round parasite protection. Credelio's rapid and sustained speed of tick kill helps protect pets against pathogen-carrying ticks which can result in dangerous diseases."1 The study included dogs that were randomly allocated to one of four treatment groups: Credelio, Simparica TRIO, NexGard or untreated control. Live tick counts were performed on dogs by blinded investigators during regular intervals.1 The study results found that by all 12-hour evaluation intervals, only the Credelio group significantly reduced lone star ticks as compared to the untreated control group. The study observed that the Simparica TRIO and NexGard groups were not significantly different from the untreated control group by any of the 12-hour evaluation intervals. The study also showed that Credelio significantly reduced ticks at all 12- and 24-hour evaluation time points and only Credelio provides a rapid speed of kill throughout the entire month-long treatment period.1,2,3 Of the evaluated products, only Credelio killed ticks as fast at the end of the month as at the beginning of the month. "This study sets Credelio apart from competitors as it maintains a rapid speed of tick kill throughout the entire monthly dosing period," said David Gosche, DVM, Elanco Sr. Director of Technical Marketing.1,2,3 "This product maintains consistent levels of efficacy in tick kill throughout the month, outperforming the competitors tested." 1,2,3 Learn more about Credelio for dogs here. To read the full study findings, click here. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability Initiatives –all to advance the health of animals, people, and the planet. CREDELIO INDICATIONS Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older and weighing 4.4 pounds or greater. CREDELIO IMPORTANT SAFETY INFORMATION Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, polyuria, and diarrhea. For full prescribing information see Credelio package insert. NexGard is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. Simparica TRIO is a registered trademark of Zoetis Services LLC. Credelio, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Other company and product names are trademarks of their respective owners. © 2024 Elanco or its affiliates PM-US-24-1168 1 Ambylomma americanum (lone star tick) 2 Reif KE, Kollasch TM, Neilson JC, Herrin BH, Ryan WG, Bell MC, Beltz MS, Dryden MW, Jesudoss Chelladurai JRJ, Miller KR, Sutherland CJ. Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs. Parasite Vectors. 2024 Jul 20;17(1):313. 3 Based on the time to statistical significance vs control in a single study on days 21 and 28 for reinfestations. 4 Centers for Disease Control and Prevention. (n.d.). Tickborne Disease Surveillance Data Summary. Centers for Disease Control and Prevention. Retrieved August 8, 2024, from 5 Companion Animal Parasite Council | 2023 Annual Pet Parasite Forecasts (capcvet.org) 6 Centers for Disease Control and Prevention. (n.d.). Where Ticks Live. Centers for Disease Control and Prevention. Retrieved August 8, 2024, from Investor Contact: Katy Grissom (317) 273-9284 [email protected] Media Contact: Season Solorio (765) 316-0233 [email protected] SOURCE Elanco Animal Health

Clinical ResultClinical Study

100 Deals associated with Moxidectin

External Link

KEGG	Wiki	ATC	Drug Bank
D05084	Moxidectin	P02CX03	DB11431

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Onchocerciasis	United States	Medicines Development for Global Health Ltd	13 Jun 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Scabies	Phase 3	Fiji	Medicines Development for Global Health Ltd	01 Mar 2026
Strongyloidiasis	Phase 3	Fiji	Medicines Development for Global Health Ltd	01 Mar 2026
Elephantiasis, Filarial	Phase 3	Côte d'Ivoire	Medicines Development for Global Health Ltd	03 May 2021
Elephantiasis, Filarial	Phase 3	Republic of the Congo	Medicines Development for Global Health Ltd	03 May 2021
Intestinal Helminthiasis	Phase 2	Australia	Medicines Development for Global Health Ltd	09 Aug 2022
Onchocerciasis, Ocular	Phase 1	United States	Medicines Development for Global Health Ltd	01 Jan 2017
Infectious Diseases	Phase 1	France	Wyeth AB	01 Nov 2008
Infectious Diseases	Phase 1	United Kingdom	Wyeth AB	01 Nov 2008
Lice Infestations	Preclinical	Australia	Medicines Development for Global Health Ltd	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06188715 (Moxiped, CTgov)	Phase 3	Trichuriasis \| Hookworm Infections \| Ascariasis	224	Albendazole 400 mg Oral Tablet+Moxidectin 2 mg Oral Tablet (Arm A: Moxidectin 4/8 mg & Albendazole)	senovpejaj = mqngjwizlc txxhjddilj (zrgshjswus, jccfejffnm - dejzerxxdj) View more	-	19 Sep 2025
				Placebo Mox+Albendazole 400 mg Oral Tablet (Arm B: Albendazole)	senovpejaj = vmgpbijxhq txxhjddilj (zrgshjswus, auzaaofsaf - ypvqiafdgu) View more
NCT04056325 (StrongMoxi, CTgov)	Phase 2/3	Strongyloidiasis	617	Moxidectin (Phase 2a - Arm A (Moxidectin 2 mg))	idqmdpywxf = cqkhmcjrjm khtwkpbilt (iqihgbpnjw, hkirujdldu - hbxdudqdmv) View more	-	09 Dec 2024
				Moxidectin (Phase 2a - Arm B (Moxidectin 4 mg))	idqmdpywxf = debghlnovs khtwkpbilt (iqihgbpnjw, owuznmtliv - ylivdhblzk) View more
NCT04700423 (CTgov)	Phase 2/3	Trichuriasis \| Hookworm Infections \| Ascariasis ... View more	536	albendazole+moxidectin (A: Moxidectin (8 mg) / Albendazole (400 mg))	ecynjiyamn(qmhzlpcgue) = ktuvmhoduc varaslkicg (jvdhgbcicy, zftcfsviyg - duldshqblo) View more	-	05 Dec 2024
				albendazole+ivermectin (B: Ivermectin (200 µg/kg) / Albendazole (400 mg))	ecynjiyamn(qmhzlpcgue) = qmfroskgyw varaslkicg (jvdhgbcicy, siofcacwsd - nuxdnfphow) View more
NCT04049851 (Pubmed)	Phase 2	Loiasis \| Onchocerciasis, Ocular	72	Moxidectin 2mg	acbgqwccbp(eyclmeclmx) = 49 AEs occurred in the MOX arm vs 59 AEs in the IVM arm mqhayhsxrv (qigvvypuhp ) View more	Positive	28 Jun 2024
				Ivermectin 150µg/kg
NCT04848688 (StrongMoxi_KH, CTgov)	Phase 3	Strongyloidiasis	332	Placebo+Moxidectin 2 mg (Moxidectin)	hjqquuhrxn = xqyswernhq rplrwezhtp (lbbhgllmot, brzmyizbxf - imsnkosykq) View more	-	24 Jan 2024
				Placebo+Ivermectin 3 mg (Ivermectin)	hjqquuhrxn = tmzdsmpuka rplrwezhtp (lbbhgllmot, vapetjeoqf - tevieirgbg) View more
NCT03905265 (CTgov)	Phase 2	Scabies	22	Moxidectin Oral Product (Moxidectin 2 mg)	zfoaqxlolq = eikcgohmpa aikrqfmges (pxbptxtqcg, tdqtgezqym - wfuvxgtfaj) View more	-	22 Sep 2023
				Moxidectin Oral Product (Moxidectin 8 mg)	zfoaqxlolq = wrnrxeubij aikrqfmges (pxbptxtqcg, yrgyxjtlin - xampakfrzt) View more
NCT04410406 (Pubmed \| PLoS Negl Trop Dis)	Phase 3	Elephantiasis, Filarial Wuchereria bancrofti microfilaremia	-	ivermectin + albendazole	rqckvqqfeu(uvsuebpxhz) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) yyglcdqiya (oaqhmalmrp ) View more	Positive	18 Sep 2023
				moxidectin + albendazole
NCT04726969 (CTgov)	Phase 3	Trichuriasis \| Hookworm Infections \| Ascariasis	255	Albendazole 400 mg Oral Tablet+Moxidectin 2 mg Oral Tablet (Arm A: Moxidectin and Albendazole)	uxftgtgnez = kncpmcvovs wcmqebmbpc (njzvsxmder, yrdewwjums - kvuuqvraxr) View more	-	02 Feb 2023
				Albendazole 400 mg Oral Tablet (Arm B: Albendazole)	uxftgtgnez = zmarlxiokx wcmqebmbpc (njzvsxmder, hktkfrkelm - zzvbhnyxex) View more
NCT00790998 (Pubmed \| PLoS Negl Trop Dis)	Phase 3	-	1,497	Moxidectin 8 mg	ksxzmkkbly(lmdutpbklb) = sacgxxdihs ttrbzyqlix (utixzdorgo )	Positive	27 Apr 2022
				Ivermectin 150 μg/kg	ksxzmkkbly(lmdutpbklb) = ubplhfqhcn ttrbzyqlix (utixzdorgo )
NCT04056325 (Pubmed \| Clin Pharmacokinet)	Phase 2	Strongyloidiasis	96	Moxidectin	faifdnrtsk(ezfwvzfuvm) = tdshjgvlkv fkwmoffxnm (wbsqhzbxir, 3.63 - 5.39) View more	-	23 Jul 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis